The FDA granted a supplemental approval for Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase (human recombinant)) on October 17, 2025. This approval, issued to sponsor ARGENX BV, specifically addresses efficacy.
Background
Vyvgart Hytrulo, known generically as efgartigimod alfa and hyaluronidase (human recombinant), received this supplemental approval from the FDA. Supplemental applications typically involve changes to an approved product, such as new indications, dosing regimens, or manufacturing changes. In this instance, the approval focused on efficacy.
What this means
A supplemental approval for efficacy indicates that the FDA has reviewed additional data supporting the drug's effectiveness. This could mean an expansion of its approved uses, a new patient population, or updated information regarding its therapeutic benefits. For clinicians, this implies potential new applications or confirmed efficacy in specific contexts for Vyvgart Hytrulo.
Source
The information regarding this supplemental approval was obtained from the FDA. The approval for BLA 761304 S-10, concerning Vyvgart Hytrulo, was granted on October 17, 2025, and is documented on accessdata.fda.gov.